Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IGCS 2022 | Optimal management of recurrent low grade endometrial cancer

Mansoor Mirza • 29 Sep 2022
IGCS 2022 IGCS 2022
Endometrial Cancer Gynecological Cancer Letrozole Selinexor
PALEO

Mansoor R. Mirza, MD, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, provides an overview of the management of endometrial cancer, including the role of endocrine therapy in low-grade disease, updates in molecular classification, and ongoing efforts of personalized medicine. This interview took place at the Annual Global Meeting of the International Gynecologic Cancer Society (IGCS 2022) in New York City, NY.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Mansoor Mirza

2:11
Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer
Mansoor Mirza • 29 Sep 2022
2:20
ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer
Mansoor Mirza • 24 Oct 2021
8:20
Immune checkpoint inhibitors for endometrial and cervical cancer
Mansoor Mirza • 24 Oct 2021
2:00
Highlights of ESGO 2021 for young researchers
Mansoor Mirza • 24 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals